人类坎比洛巴克特 spp. 意大利的感染情况
Verena Zerbato1, Stefano Di Bella2, Riccardo Pol3
1Infectious Diseases Unit, Trieste University Hospital (ASUGI), Trieste, Italy. verena.zerbato@gmail.com.
概括
意大利的坎比洛巴克菌感染表明对诺基诺和四环素的耐药性正在下降. 然而,宏类药物对这些常见的肠道病原体仍然有效.
科学领域:
- 微生物学 微生物学
- 传染性疾病 传染性疾病
- 流行病学 流行病学
背景情况:
- 全球范围内,坎比洛巴克特菌种是细菌性胃肠炎的首要原因.
- 坎比洛巴克的抗菌素耐药性构成了重大的公共卫生挑战.
- 最近关于意大利坎皮洛巴克特菌感染的流行病学数据仅限于2013-2016年.
研究的目的:
- 分析意大利国家流行病学和微生物学数据,以分析人类的坎皮洛巴克特菌感染情况.
- 追踪2017-2021年间Campylobacter物种抗菌素耐药性模式的趋势.
主要方法:
- 来自意大利13个地区的19家医院收集的数据.
- 使用质谱法进行细菌鉴定.
- 通过Etest或Kirby-Bauer方法 (EUCAST标准) 进行抗菌敏感性测试.
主要成果:
- 确定了超过5400个坎皮洛巴克特菌分离体,主要是C. jejuni (83.7%) 和C. coli (13.5%).
- 观察到高耐药率的西普洛素 (75.5%) 和四环素 (54.8%).
- 在研究期间,对宏类药物 (erythromycin,clarithromycin,azithromycin) 的耐药性仍然很低 (<5%),并且对西普洛素和四环素显著下降.
结论:
- 在意大利,坎皮洛巴克特对诺和四环素的耐药性正在下降,但仍然很高.
- 宏类抗生素在意大利对坎皮洛巴克特菌感染保持良好疗效.
- 持续监测对于监测抗菌素耐药性趋势至关重要.
关键词:
坎比洛巴克特 (Campylobacter jejuniuni) 是一个常见的菌类.(6): 坎比洛巴克特 sppp.抗微生物耐药性 抗微生物耐药性意大利 意大利 意大利 意大利具有多种药物耐药性的药物.监督 监督 监督 监督 监督 监督更多相关视频
08:23Culture Methods to Determine the Limit of Detection and Survival in Transport Media of Campylobacter Jejuni in Human Fecal Specimens
Published on: March 10, 2020
11.5K
05:34Author Spotlight: Development of an Enhanced Protocol for Rapid and Accurate Isolation of Campylobacter from Food Products
Published on: February 23, 2024
1.9K
相关概念视频
01:30Reservoir of Infection
Infectious diseases arise from intricate interactions between pathogens and their reservoirs. A reservoir of infection refers to the natural habitat where a pathogen lives, grows, and multiplies, serving as a continual source of infection. Reservoirs are broadly classified as either living or nonliving, and each plays a unique role in disease transmission, significantly influencing public health interventions and control strategies.Humans act as reservoirs for a wide array of pathogens,...
01:23Investigation of Disease Outbreaks
Multistate foodborne outbreaks pose significant public health risks and require meticulous investigation to identify sources and implement control measures. The Centers for Disease Control and Prevention (CDC) utilizes a dynamic seven-step process for these investigations, integrating data from laboratories, interviews, and environmental assessments to protect public health.Outbreak Detection: The detection of multistate outbreaks typically begins with PulseNet, the CDC's national laboratory...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:18Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
01:12Giardiasis
Giardiasis is a globally prevalent intestinal infection caused by the protozoan parasite Giardia duodenalis (also known as G. lamblia or G. intestinalis). This flagellated protozoan is the most frequently identified intestinal parasite in the United States and worldwide. Transmission primarily occurs via the fecal-oral route, with infection arising from ingestion of water or food contaminated with cysts. Individuals in low-resource settings, international travelers, outdoor enthusiasts, daycare...
01:28Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...